DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by oka varicella vaccine

Journal of Infectious Diseases

Volumn 195, Issue 4, 2007, Pages 502-510

  Loparev, Vladimir N ^a   Rubtcova, Elena ^a   Seward, Jane F ^a   Levin, Myron J ^b   Schmid, D Scott ^a,c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b Children's Hospital Colorado   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; IMMEDIATE EARLY PROTEIN; IMMEDIATE EARLY PROTEIN 62; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; DNA SEQUENCE; GENE FREQUENCY; GENETIC VARIABILITY; HERPES ZOSTER; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; RECIPIENT; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; VARICELLA ZOSTER VIRUS; VIRUS GENOME; VIRUS ISOLATION; VIRUS LATENCY; VIRUS STRAIN; WILD TYPE;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; BASE SEQUENCE; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; DNA, VIRAL; HERPES ZOSTER; HERPESVIRUS 3, HUMAN; HUMANS; INFANT; MIDDLE AGED; MUTATION; OPEN READING FRAMES; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 33846809498     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510532     Document Type: Article

References (36)

1. Choo PW, Donahue JG, Manson JE, Platt R. The epidemiology of varicella and its complications. J Infect Dis 1995; 172:706-12.
2. Galil K, Fair E, Mountcastle N, Britz P, Seward JF. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002; 186:102-5.
3. Heininger U, Seward JF. Varicella. Lancet 2006; 368:1365-76.
4. Arvin AM. Varicella-zoster virus. In: Knipe DM, Howley PM, eds. Fields' virology. Philadelphia: Lippincott, Williams and Wilkins, 2001:2731-67.
5. Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella-zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127:305-14.
6. Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58:9-20.
7. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974;2:1288-90.
8. Gomi Y, Imagawa T, Takahashi M, Yamanishi K. Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity. J Med Virol 2000; 61:497-503.
9. Gomi Y, Imagawa T, Takahashi M, et al. Comparison of DNA sequence and transactivation activity of open reading frame 62 of Oka varicella vaccine and its parental viruses. Arch Virol 2001; Suppl 17:49-56.
10. Gomi Y, Sunamachi H, Mori Y, Nagaike K, Takahashi M, Yamanishi K. Comparison of the complete DNA sequences of the Oka varicella vaccine and its parental virus. J Virol 2002; 76:11447-59.
11. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus. J Infect Dis 2004; 190:793-6.
12. Sauerbrei A, Rubtcova E, Wutzler P, Scmid DS, Loparev VN. Genetic profile of an Oka varicella vaccine variant isolated from an infant with zoster. J Clin Microbiol 2004; 42:5604-8.
13. National Advisory Committee on Immunization (NACI). An Advisory Committee statement (ACS). NACI update to statement on varicella vaccine. Can Commun Dis Rep 2002; 28:1-7.
14. División Epidemiología. Boletín Oficial 2001: coberturas vacunales. Montevideo, Uruguay: Ministerio de Salud Pública, 2001.
15. National Health and Medical Research Council. The Australian Immunisation Handbook. 8th ed. Canberra: Australian Government Publishing Service, 2003:240-52.
16. Pinot de Moira A, Nardone A. Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill 2005; 10:43-5.
17. Gershon AA. The current status of live attenuated varicella vaccine. Arch Virol 2001; Suppl 17:1-6.
18. Izurieta HS, Strebel PM, Blake PA. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. JAMA 1997; 278:1495-9.
19. Marin M, Nguyen HQ, Keen J, et al. Importance of catch-up vaccination: experience from a varicella outbreak, Maine, 2002-2003. Pediatrics 2005; 115:900-5.
20. Seward JF. Update on varicella. Pediatr Infect Dis J 2001; 20:619-21.
21. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA 2004; 292:704-8.
22. Vázquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA 2004; 291:851-5.
23. Nguyen H, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005; 352:450-8.
24. Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002; 287:606-11.
25. Zhou F, Harpaz R, Jumaan AO, Winston CA, Shefer A. Impact of varicella vaccination on health care utilization. JAMA 2005; 294:797-802.
26. Weibel RE, Neff BJ, Kuter BJ, et al. Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med 1984; 310:1409-15.
27. Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA 2000; 284:1271-9.
28. Sharrar RG, LaRussa P, Galea SA, et al. The postmarketing safety profile of varicella vaccine. Vaccine 2000; 19:916-23.
29. Sauerbrei A, Uebe B, Wutzler P. Molecular diagnosis of zoster post varicella vaccination. J Clin Virol 2003; 27:190-9.
30. Uebe B, Sauerbrei A, Burdach S, Horneff G. Herpes zoster by reactivated vaccine varicella-zoster virus in a healthy child. Eur J Pediatr 2002; 161:442-4.
31. Hardy I, Gershon AA, Steinberg SP, LaRussa P. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. Varicella Vaccine Collaborative Study Group. N Engl J Med 1991; 325:1545-50.
32. Argaw T, Cohen JI, Klutch M, et al. Nucleotide sequences that distinguish Oka vaccine from parental Oka and other varicella zoster isolates. J Infect Dis 2000; 181:1153-7.
33. La Russa P, Lungu O, Hardy I, et al. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J Virol 1992; 66:1016-20.
34. Loparev VN, Argaw T, Krause PR, et al. Improved identification and differentiation of varicella-zoster virus (VZV) wild-type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J Clin Microbiol 2000; 38:3156-60.
35. Loparev VN, McCaustland K, Holloway BP, et al. Rapid genotyping of varicella-zoster virus vaccine and wild-type strains with fluorophore-labeled hybridization probes. J Clin Microbiol 2000; 38:4315-9.
36. Dayan GH, Panero MS, Debbag R, et al. Varicella seroprevalence and molecular epidemiology of varicella-zoster virus in Argentina, 2002. J Clin Microbiol 2004; 42:5698-704.